CT 071
Alternative Names: CT-071; GPRC5D targeted CAR T cell therapy - CARsgen TherapeuticsLatest Information Update: 28 May 2026
At a glance
- Originator CARsgen
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase 0 Multiple myeloma
- No development reported Leukaemia
Most Recent Events
- 28 May 2026 No recent reports of development identified for phase-0 development in Leukaemia(Second-line therapy or greater) in China (Parenteral, Injection)
- 28 May 2026 No recent reports of development identified for phase-0 development in Multiple-myeloma(Second-line therapy or greater) in China (Parenteral, Injection)
- 08 Oct 2025 Efficacy and adverse event data from a phase 0 trial in Multiple myeloma released by CARsgen Therapeutics